Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Novel Antimicrobial Agents
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Novel Antimicrobial Agents

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".

Deadline for manuscript submissions: 30 August 2024 | Viewed by 2514

Special Issue Editor

Dr. Inês Bártolo

E-Mail Website
Guest Editor
imed.Ulisboa, Faculty of Pharmacy, Lisbon University, 1649-019 Lisbon, Portugal
Interests: the search for new compounds with anti-HIV activity and against respiratory viruses; the development of microbicide candidates to prevent HIV infection

Special Issue Information

Dear Colleagues,

The need for novel antimicrobial agents is pressing due to the increasing prevalence of antimicrobial-resistant microorganisms. Antimicrobial resistance (AMR) is a major global health threat that has been exacerbated by the overuse and misuse of antimicrobials. AMR occurs when microorganisms evolve to become resistant to the drugs that are designed to kill them, leading to the development of so-called “superbugs” that are difficult or impossible to treat. These “superbugs” can cause severe infections and are a major concern for public health. To combat the growing problem of AMR, it is crucial to develop new antimicrobial agents that can effectively kill these resistant microorganisms. These novel agents could include new types of antibiotics, as well as antivirals, antifungals, and antiparasitics. In addition to developing these agents, it is also important to ensure that they are used responsibly in order to minimize the development of resistance. Overall, the need for novel antimicrobial agents is crucial for protecting public health and addressing the global threat of AMR. By investing in research and development of these agents, we can help to ensure that we have the tools necessary to effectively treat infectious diseases and keep communities healthy.

Dr. Inês Bártolo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug resistance
  • antimicrobial resistance (AMR)
  • drug-resistant bacteria
  • drug-resistant viruses
  • drug-resistant fungi
  • drug-resistant parasite
  • drug resistance biomolecular studies
  • mechanism of resistance
  • novel antimicrobial agents
  • treatment of infectious diseases

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

20 pages, 4084 KiB  
Article
Inhibitors of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Decrease the Growth, Ergosterol Synthesis and Generation of petite Mutants in Candida glabrata and Candida albicans
by Dulce Andrade-Pavón, Eugenia Sánchez-Sandoval, Joaquín Tamariz, Jose Antonio Ibarra, César Hernández-Rodríguez and Lourdes Villa-Tanaca
Int. J. Mol. Sci. 2023, 24(23), 16868; https://doi.org/10.3390/ijms242316868 - 28 Nov 2023
Viewed by 761
Abstract
Candida glabrata and Candida albicans, the most frequently isolated candidiasis species in the world, have developed mechanisms of resistance to treatment with azoles. Among the clinically used antifungal drugs are statins and other compounds that inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR), resulting [...] Read more.
Candida glabrata and Candida albicans, the most frequently isolated candidiasis species in the world, have developed mechanisms of resistance to treatment with azoles. Among the clinically used antifungal drugs are statins and other compounds that inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR), resulting in decreased growth and ergosterol levels in yeasts. Ergosterol is a key element for the formation of the yeast cell membrane. However, statins often cause DNA damage to yeast cells, facilitating mutation and drug resistance. The aim of the current contribution was to synthesize seven series of compounds as inhibitors of the HMGR enzyme of Candida ssp., and to evaluate their effect on cellular growth, ergosterol synthesis and generation of petite mutants of C. glabrata and C. albicans. Compared to the reference drugs (fluconazole and simvastatin), some HMGR inhibitors caused lower growth and ergosterol synthesis in the yeast species and generated fewer petite mutants. Moreover, heterologous expression was achieved in Pichia pastoris, and compounds 1a, 1b, 6g and 7a inhibited the activity of recombinant CgHMGR and showed better binding energy values than for α-asarone and simvastatin. Thus, we believe these are good candidates for future antifungal drug development. Full article
(This article belongs to the Special Issue Novel Antimicrobial Agents)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

18 pages, 4831 KiB  
Review
The Potential Role of Nitric Oxide as a Therapeutic Agent against SARS-CoV-2 Infection
by Shuqi Xiao, Zhiming Yuan and Yi Huang
Int. J. Mol. Sci. 2023, 24(24), 17162; https://doi.org/10.3390/ijms242417162 - 05 Dec 2023
Cited by 1 | Viewed by 1031
Abstract
The global coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become the greatest worldwide public health threat of this century, which may predispose multi-organ failure (especially the lung) and death despite numerous mild and moderate [...] Read more.
The global coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become the greatest worldwide public health threat of this century, which may predispose multi-organ failure (especially the lung) and death despite numerous mild and moderate symptoms. Recent studies have unraveled the molecular and clinical characteristics of the infectivity, pathogenicity, and immune evasion of SARS-CoV-2 and thus improved the development of many different therapeutic strategies to combat COVID-19, including treatment and prevention. Previous studies have indicated that nitric oxide (NO) is an antimicrobial and anti-inflammatory molecule with key roles in pulmonary vascular function in the context of viral infections and other pulmonary disease states. This review summarized the recent advances of the pathogenesis of SARS-CoV-2, and accordingly elaborated on the potential application of NO in the management of patients with COVID-19 through antiviral activities and anti-inflammatory properties, which mitigate the propagation of this disease. Although there are some limits of NO in the treatment of COVID-19, it might be a worthy candidate in the multiple stages of COVID-19 prevention or therapy. Full article
(This article belongs to the Special Issue Novel Antimicrobial Agents)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop